Company Summary:
FL89, Inc. is a privately held early-stage company that is leveraging advanced biological and computational tools to develop breakthroughs in our understanding of secreted protein function and regulation in human physiology. More specifically, FL89 is pairing high throughput -omics technology with AI/ML based protein structure prediction to define and discover novel therapeutic protein biology.
Flagship Pioneering has conceived of and created companies such as Moderna Therapeutics (NASDAQ: MRNA), Editas Medicine (NASDAQ: EDIT), Omega Therapeutics (NASDAQ: OMGA), Seres Therapeutics (NASDAQ: MCRB), and Indigo Agriculture. Since its launch in 2000, Flagship has applied its unique hypothesis-driven innovation process to originate and foster more than 100 scientific ventures. In 2021, Flagship Pioneering was ranked 12th globally on Fortune’s “Change the World” list, an annual ranking of companies that have made a positive social and environmental impact through activities that are part of their core business strategies.
Position Summary:
Part of a collaborative team with a focus on developing high-throughput next-generation sequencing platforms and cell models to enable discovery in the FL89 secretome platform. This individual will utilize previous experiences in generation and analyses of large next-generation sequencing datasets to drive development of a novel biological platform. The position will provide a unique opportunity to play a foundational role in the development of FL89’s preclinical platform.
Key Responsibilities:
Basic Requirements:
Preferred Requirements:
Flagship Pioneering is committed to equal employment opportunity regardless of race, color, ancestry, religion, sex, national origin, sexual orientation, age, citizenship, marital status, disability, gender identity or Veteran status.